Legato Capital Management LLC Has $677,000 Position in Guardant Health, Inc. $GH

Legato Capital Management LLC cut its position in Guardant Health, Inc. (NASDAQ:GH) by 59.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,835 shares of the company’s stock after selling 16,084 shares during the quarter. Legato Capital Management LLC’s holdings in Guardant Health were worth $677,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Baillie Gifford & Co. lifted its holdings in shares of Guardant Health by 6.6% during the third quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock worth $320,378,000 after buying an additional 317,906 shares in the last quarter. Invesco Ltd. increased its position in Guardant Health by 27.3% during the second quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after acquiring an additional 763,834 shares during the period. Geode Capital Management LLC raised its stake in Guardant Health by 0.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,920,714 shares of the company’s stock worth $152,014,000 after purchasing an additional 13,088 shares in the last quarter. Franklin Resources Inc. raised its stake in Guardant Health by 78.2% in the 2nd quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock worth $120,730,000 after purchasing an additional 1,018,144 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. boosted its holdings in Guardant Health by 49.6% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company’s stock valued at $105,623,000 after purchasing an additional 673,438 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $93.02 on Thursday. Guardant Health, Inc. has a 52-week low of $34.88 and a 52-week high of $120.74. The firm has a market cap of $12.20 billion, a price-to-earnings ratio of -28.10 and a beta of 1.67. The business’s fifty day moving average is $105.73 and its 200-day moving average is $88.45.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period in the prior year, the company posted ($0.62) EPS. The firm’s revenue was up 39.4% compared to the same quarter last year. As a group, research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. UBS Group reaffirmed a “buy” rating and set a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. JPMorgan Chase & Co. raised their price objective on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. TD Cowen lifted their price objective on Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Finally, Wells Fargo & Company raised their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $122.57.

Insider Buying and Selling

In other news, insider Terilyn J. Monroe sold 8,571 shares of the company’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the completion of the transaction, the insider directly owned 20,990 shares in the company, valued at approximately $2,394,749.10. This represents a 28.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helmy Eltoukhy sold 90,565 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $103.82, for a total value of $9,402,458.30. Following the completion of the transaction, the chief executive officer owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. The trade was a 4.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 379,344 shares of company stock worth $39,734,840 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.